Beyond tirzepatide, other incretin-based therapies have shown promise, such as retatrutide, a novel triple-hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, with early-phase trials demonstrating profound effects on weight reduction [36]
A well-formulated compound is designed for optimal diffusion in this specific environment
Fatty acid synthase as a potential therapeutic target in cancer
McDonald said that if a causal link is proven, thsi could have implicatiosn for otehr cancer types, such as lung, colon, and liver cancer, leukemia and multiple myeloma But observational studies all have some level of bias, despite sophisticated methods to control for this